263TiP Implementing geriatric assessment for dose optimization of CDK 4/6-inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial
Antonios Valachis(Örebro University Hospital), T. Kosmidis, Helena Linardou(Metropolitan Hospital), R. Gomez-Bravo(Hospital Clínic de Barcelona), P.A. Kosmidis(Hygeia Hospital), Kamilla Fjermeros(Akershus University Hospital), Aglaia Schiza(Uppsala University Hospital), Emanuela Risi(Unknown), Laura Biganzoli(Hospital of Prato), A.N. Christopoulou(Agios Andreas Hospital), Meri Utriainen(University of Helsinki), Henrik Lindman(Uppsala University), I. Meattini(Azienda Ospedaliero-Universitaria Careggi), A. Psyrri(University General Hospital Attikon), L. Visani(Azienda Ospedaliero-Universitaria Careggi), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Elena Fountzilas(St. Luke's Hospital), P. Karihtala(Helsinki University Hospital), A. Koutras(General University Hospital of Patras), J. Geisler(Akershus University Hospital)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504